(Reuters) -Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company’s shares 23% higher in premarket trading on Friday.

The company was testing the efficacy of its experimental outpatient procedure called Revita, which modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly’s weight-loss drug.

The study showed that people who underwent the procedure lost an additional 2.5% weight three months after stopping the drug, while others in the trial who had a sham procedure gained back 10% of their weight, the company said.

The procedure also demonstrated favorable safety and tolerability, Fractyl said.

Revita has U.S. FDA Breakthrough Device desig

See Full Page